← All trials
NCT05238831
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2022
- Primary completion
- Mar 31, 2026
- Completion date
- Mar 31, 2026
- First posted
- Feb 14, 2022
- Last posted
- Jul 14, 2022
- Enrollment
- 131
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- OHSU Knight Cancer InstituteLead sponsor
- GenentechCollaborator
- Oregon Health and Science UniversityCollaborator
- OHSU Knight Cancer InstituteOverall official - principal investigator
- OHSU Knight Cancer InstituteReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.